Ausgabe 6/2017
Inhalt (14 Artikel)
Acknowledgement to Referees
The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions
Angel Qin, Shirish Gadgeel
Antibody–Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments
Aiko Nagayama, Leif W. Ellisen, Bruce Chabner, Aditya Bardia
Targeting FGFR in Squamous Cell Carcinoma of the Lung
Neda Hashemi-Sadraei, Nasser Hanna
The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors
Fabiola Amair-Pinedo, Ignacio Matos, Tamara Saurí, Jorge Hernando, Jaume Capdevila
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
Zev A. Wainberg, Maria Alsina, Heloisa P. Soares, Irene Braña, Carolyn D. Britten, Gianluca Del Conte, Patrick Ezeh, Brett Houk, Kenneth A. Kern, Stephen Leong, Nuzhat Pathan, Kristen J. Pierce, Lillian L. Siu, Jennifer Vermette, Josep Tabernero
CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer
Yu Sunakawa, Akihito Tsuji, Tadamichi Denda, Yoshihiko Segawa, Yuji Negoro, Ken Shimada, Mitsugu Kochi, Masato Nakamura, Masahito Kotaka, Hiroaki Tanioka, Akinori Takagane, Satoshi Tani, Tatsuro Yamaguchi, Takanori Watanabe, Masahiro Takeuchi, Masashi Fujii, Wataru Ichikawa
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma
Giovan Giuseppe Di Costanzo, Andrea Casadei Gardini, Giorgia Marisi, Francesco Giuseppe Foschi, Mario Scartozzi, Rocco Granata, Luca Faloppi, Stefano Cascinu, Nicola Silvestris, Oronzo Brunetti, Vincenzo Ostilio Palmieri, Giorgio Ercolani, Raffaella Tortora
Comparative Safety of Targeted Therapies for Metastatic Colorectal Cancer between Elderly and Younger Patients: a Study Using the International Pharmacovigilance Database
Amandine Gouverneur, Pauline Claraz, Marine Rousset, Mickaël Arnaud, Annie Fourrier-Réglat, Antoine Pariente, Thomas Aparicio, Ghada Miremont-Salamé, Pernelle Noize
Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
Anke E. M. van Erp, Melissa H. S. Hillebrandt-Roeffen, Laurens van Houdt, Emmy D. G. Fleuren, Winette T. A. van der Graaf, Yvonne M. H. Versleijen-Jonkers
Impact of Imatinib on the Fertility of Male Patients with Chronic Myelogenous Leukaemia in the Chronic Phase
Xiaohui Chang, Lin Zhou, Xiaoxia Chen, Baoli Xu, Yubin Cheng, Shujun Sun, Meiyun Fang, Yang Xiang
Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02–14 Study)
Jean-Bernard Auliac, Isabelle Monnet, Catherine Dubos-Arvis, Anne Marie Chiappa, Nathalie Baize, Suzana Bota, Alain Vergnenegre, Helene Doubre, Chrystele Locher, Acya Bizieux, Gilles Robinet, Christos Chouaid
Author’s Reply to Arnaud Uguen: “Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02–14 Study)”
Jean-Bernard Auliac, Christos Chouaid